{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:15:46Z","timestamp":1792088146113,"version":"4.4.0"},"reference-count":205,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministry of Education Youth and Sports","doi-asserted-by":"publisher","award":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000785"],"award-info":[{"award-number":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000785"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministry of Education Youth and Sports","doi-asserted-by":"publisher","award":["LM2018133"],"award-info":[{"award-number":["LM2018133"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"publisher","award":["Cooperatio Program, research area \u201eOncology and Haematooncology\""],"award-info":[{"award-number":["Cooperatio Program, research area \u201eOncology and Haematooncology\""]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Dipeptidyl peptidase IV (DPP-IV, CD26) is frequently dysregulated in cancer and plays an important role in regulating multiple bioactive peptides with the potential to influence cancer progression and the recruitment of immune cells. Therefore, it represents a potential contributing factor to cancer pathogenesis and an attractive therapeutic target. Specific DPP-IV inhibitors (gliptins) are currently used in patients with type 2 diabetes mellitus to promote insulin secretion by prolonging the activity of the incretins glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Nevertheless, the modulation of the bioavailability and function of other DPP-IV substrates, including chemokines, raises the possibility that the use of these orally administered drugs with favorable side-effect profiles might be extended beyond the treatment of hyperglycemia. In this review, we critically examine the possible utilization of DPP-IV inhibition in cancer prevention and various aspects of cancer treatment and discuss the potential perils associated with the inhibition of DPP-IV in cancer. The current literature is summarized regarding the possible chemopreventive and cytotoxic effects of gliptins and their potential utility in modulating the anti-tumor immune response, enhancing hematopoietic stem cell transplantation, preventing acute graft-versus-host disease, and alleviating the side-effects of conventional anti-tumor treatments.<\/jats:p>","DOI":"10.3390\/cancers14092072","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T05:07:22Z","timestamp":1650604042000},"page":"2072","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2158-4837","authenticated-orcid":false,"given":"Petr","family":"Busek","sequence":"first","affiliation":[{"name":"Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9478-9609","authenticated-orcid":false,"given":"Jonathan S.","family":"Duke-Cohan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3247-5436","authenticated-orcid":false,"given":"Aleksi","family":"Sedo","sequence":"additional","affiliation":[{"name":"Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1615\/CritRevOncog.2015013668","article-title":"Physiological, Tumor, and Metastatic Niches: Opportunities and Challenges for Targeting the Tumor Microenvironment","volume":"20","author":"Murgai","year":"2015","journal-title":"Crit. Rev. Oncog."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12781","article-title":"Cut to the chase: A review of CD26\/dipeptidyl peptidase-4\u2019s (DPP4) entanglement in the immune system","volume":"185","author":"Klemann","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lichtor, T. (2013). Dipeptidyl Peptidase-IV and Related Proteases in Brain Tumors. Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications, InTech.","DOI":"10.5772\/50198"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/713609354","article-title":"Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV","volume":"40","author":"Lambeir","year":"2003","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-0115(99)00089-0","article-title":"Dipeptidyl-peptidase IV (CD26)\u2014Role in the inactivation of regulatory peptides","volume":"85","author":"Mentlein","year":"1999","journal-title":"Regul. Pept."},{"key":"ref_7","first-page":"334","article-title":"NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis","volume":"8","author":"Wang","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12032-020-01419-0","article-title":"The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2\/HO1 pathway","volume":"37","author":"He","year":"2020","journal-title":"Med. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1046\/j.1432-1327.2000.01634.x","article-title":"Molecular characterization of dipeptidyl peptidase activity in serum: Soluble CD26\/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides","volume":"267","author":"Durinx","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"D343","DOI":"10.1093\/nar\/gkr987","article-title":"MEROPS: The database of proteolytic enzymes, their substrates and inhibitors","volume":"40","author":"Rawlings","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pharmthera.2019.02.005","article-title":"What doesn\u2019t kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands","volume":"198","author":"Elmansi","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2021). Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care, 44, S111\u2013S124.","DOI":"10.2337\/dc21-S009"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.13135","article-title":"A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials","volume":"20","author":"Deacon","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00535-013-0783-4","article-title":"Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats","volume":"49","author":"Kaji","year":"2014","journal-title":"J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/med.21513","article-title":"Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection","volume":"39","author":"Tomovic","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1210\/jc.2012-1544","article-title":"Sitagliptin exerts an antinflammatory action","volume":"97","author":"Makdissi","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.biochi.2019.11.005","article-title":"Amelioration of diet-induced metabolic syndrome and fatty liver with sitagliptin via regulation of adipose tissue inflammation and hepatic Adiponectin\/AMPK levels in mice","volume":"168","author":"Prakash","year":"2020","journal-title":"Biochimie"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/jcmm.12465","article-title":"Sitagliptin attenuates sympathetic innervation via modulating reactive oxygen species and interstitial adenosine in infarcted rat hearts","volume":"19","author":"Lee","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"105805","DOI":"10.1016\/j.intimp.2019.105805","article-title":"Sitagliptin inhibits vascular inflammation via the SIRT6-dependent signaling pathway","volume":"75","author":"He","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4093\/dmj.2016.40.5.339","article-title":"Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus","volume":"40","author":"Kim","year":"2016","journal-title":"Diabetes Metab. J."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Weber, A.E., and Thornberry, N.A. (2021). Dipeptidyl Peptidase 4 Inhibitors. Burger\u2019s Medicinal Chemistry and Drug Discovery, Available online: https:\/\/onlinelibrary.wiley.com\/doi\/book\/10.1002\/0471266949.","DOI":"10.1002\/0471266949.bmc183.pub2"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2016.06.016","article-title":"Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo","volume":"788","author":"Kim","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1124\/jpet.107.135723","article-title":"(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors","volume":"325","author":"Thomas","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3109\/14756366.2014.1002402","article-title":"Anagliptin, a potent dipeptidyl peptidase IV inhibitor: Its single-crystal structure and enzyme interactions","volume":"30","author":"Watanabe","year":"2015","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0014-5793(98)00830-8","article-title":"Processing by CD26\/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha","volume":"432","author":"Proost","year":"1998","journal-title":"FEBS Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0301-472X(03)00256-X","article-title":"CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26(\u2212\/\u2212) mice","volume":"31","author":"Christopherson","year":"2003","journal-title":"Exp. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1126\/science.1097071","article-title":"Modulation of hematopoietic stem cell homing and engraftment by CD26","volume":"305","author":"Christopherson","year":"2004","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8060","DOI":"10.1038\/s41598-021-87539-7","article-title":"Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice","volume":"11","author":"Hansen","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1073\/pnas.91.14.6594","article-title":"Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): A possible mechanism for Tat\u2019s immunosuppressive activity","volume":"91","author":"Gutheil","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0014-5793(00)01751-8","article-title":"The HIV-1 gp120 inhibits the binding of adenosine deaminase to CD26 by a mechanism modulated by CD4 and CXCR4 expression","volume":"477","author":"Blanco","year":"2000","journal-title":"FEBS Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature12328","article-title":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26","volume":"500","author":"Lu","year":"2013","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4049\/jimmunol.133.3.1250","article-title":"Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody","volume":"133","author":"Fox","year":"1984","journal-title":"J. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.molimm.2020.12.009","article-title":"T cell receptor diversity, specificity and promiscuity of functionally heterogeneous human MR1-restricted T cells","volume":"130","author":"Lepore","year":"2021","journal-title":"Mol. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3389\/fimmu.2015.00387","article-title":"The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis","volume":"6","author":"Waumans","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.4049\/jimmunol.1103801","article-title":"Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26)","volume":"188","author":"Bengsch","year":"2012","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"14186","DOI":"10.1073\/pnas.0405266101","article-title":"CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1","volume":"101","author":"Ohnuma","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10117","DOI":"10.1074\/jbc.M609157200","article-title":"Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1","volume":"282","author":"Ohnuma","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/imm.12028","article-title":"CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production","volume":"138","author":"Hatano","year":"2013","journal-title":"Immunology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood.V90.4.1600","article-title":"Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion","volume":"90","author":"Huang","year":"1997","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.8101391","article-title":"Direct association of adenosine deaminase with a T cell activation antigen, CD26","volume":"261","author":"Kameoka","year":"1993","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1042\/bj3610203","article-title":"Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminase-CD26 interaction","volume":"361","author":"Gines","year":"2002","journal-title":"Biochem. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-3083.2010.02488.x","article-title":"Soluble CD26\/dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding","volume":"73","author":"Yu","year":"2011","journal-title":"Scand. J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0165-2478(00)00170-X","article-title":"Molecular analysis of CD26-mediated signal transduction in T cells","volume":"72","author":"Huhn","year":"2000","journal-title":"Immunol. Lett."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3389\/fimmu.2016.00483","article-title":"Regulation of Chemokine Activity\u2014A Focus on the Role of Dipeptidyl Peptidase IV\/CD26","volume":"7","author":"Metzemaekers","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41423-018-0009-z","article-title":"Delayed allogeneic skin graft rejection in CD26-deficient mice","volume":"16","author":"Zhao","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2249.2008.03839.x","article-title":"CD26\/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently","volume":"155","author":"Klemann","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Vora, K.A., Porter, G., Peng, R., Cui, Y., Pryor, K., Eiermann, G., and Zaller, D.M. (2009). Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. BMC Immunol., 10.","DOI":"10.1186\/1471-2172-10-19"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1515\/CCLM.2009.062","article-title":"Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: Investigations in DP IV\/CD26-knockout mice","volume":"47","author":"Reinhold","year":"2009","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"The Immunological Genome Project (2020). ImmGen at 15. Nat. Immunol., 21, 700\u2013703.","DOI":"10.1038\/s41590-020-0687-4"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"24600","DOI":"10.1074\/jbc.M303424200","article-title":"A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis","volume":"278","author":"Cheng","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1517\/17530059.2.6.677","article-title":"Dipeptidyl peptidase-IV and related molecules: Markers of malignancy?","volume":"2","author":"Sedo","year":"2008","journal-title":"Expert Opin. Med. Diagn."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2019.02.015","article-title":"CD26\/DPP4\u2014A potential biomarker and target for cancer therapy","volume":"198","author":"Enz","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1007\/s13277-016-5005-2","article-title":"DPPIV\/CD26: A tumor suppressor or a marker of malignancy?","volume":"37","author":"Beckenkamp","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/ijc.20091","article-title":"Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells","volume":"109","author":"Wesley","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/onc.2008.402","article-title":"Suppression of neuroblastoma growth by dipeptidyl peptidase IV: Relevance of chemokine regulation and caspase activation","volume":"28","author":"Arscott","year":"2009","journal-title":"Oncogene"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1084\/jem.190.3.311","article-title":"A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells","volume":"190","author":"Wesley","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood-2005-04-1492","article-title":"Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26\/dipeptidylpeptidase IV","volume":"107","author":"Narducci","year":"2006","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.2017.62","article-title":"First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers","volume":"116","author":"Angevin","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1210\/jc.2017-00346","article-title":"Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma","volume":"102","author":"Lee","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/onc.2016.291","article-title":"The promotion of the transformation of quiescent gastric cancer stem cells by IL-17 and the underlying mechanisms","volume":"36","author":"Jiang","year":"2017","journal-title":"Oncogene"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Larrinaga, G., Perez, I., Sanz, B., Beitia, M., Errarte, P., Fernandez, A., Blanco, L., Etxezarraga, M.C., Gil, J., and Lopez, J.I. (2015). Dipeptidyl-peptidase IV activity is correlated with colorectal cancer prognosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119436"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.stem.2010.04.001","article-title":"A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer","volume":"6","author":"Pang","year":"2010","journal-title":"Cell Stem Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10585-015-9736-z","article-title":"Suppression of lung metastases by the CD26\/DPP4 inhibitor Vildagliptin in mice","volume":"32","author":"Jang","year":"2015","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1600-0463.2008.01029.x","article-title":"Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines","volume":"116","author":"Goscinski","year":"2008","journal-title":"APMIS"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI131919","article-title":"Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer","volume":"130","author":"Dietrich","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41590-019-0321-5","article-title":"Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth","volume":"20","author":"Hollande","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcmgh.2018.08.008","article-title":"Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice","volume":"7","author":"Nishina","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Henderson, J.M., Xiang, M.S.W., Huang, J.C., Wetzel, S., Jiang, L., Lai, J.H., Wu, W., Kench, J.G., Bachovchin, W.W., and Roediger, B. (2021). Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13215495"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/j.1939-4640.2000.tb02099.x","article-title":"Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands","volume":"21","author":"Wilson","year":"2000","journal-title":"J. Androl."},{"key":"ref_71","first-page":"647","article-title":"Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters","volume":"18","author":"Lu","year":"2013","journal-title":"J. Res. Med. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/0008-5472.CAN-04-1852","article-title":"Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway","volume":"65","author":"Wesley","year":"2005","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10585-008-9188-9","article-title":"CD26\/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1\/CXCL12","volume":"25","author":"Sun","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1158\/0008-5472.CAN-18-0687","article-title":"Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer","volume":"78","author":"Russo","year":"2018","journal-title":"Cancer Res."},{"key":"ref_75","first-page":"785","article-title":"Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade","volume":"31","author":"Stremenova","year":"2007","journal-title":"Int. J. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"443","DOI":"10.33549\/physiolres.931231","article-title":"Modulation of substance P signaling by dipeptidyl peptidase-IV enzymatic activity in human glioma cell lines","volume":"57","author":"Busek","year":"2008","journal-title":"Physiol. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.biocel.2012.01.011","article-title":"Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity","volume":"44","author":"Busek","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1111\/bph.13274","article-title":"Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression","volume":"172","author":"Choi","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/cyto.a.22095","article-title":"Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes","volume":"81","author":"Leccia","year":"2012","journal-title":"Cytom. A"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/0008-5472.CAN-18-0620","article-title":"Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12\/CXCR4\/mTOR Axis","volume":"79","author":"Yang","year":"2019","journal-title":"Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Li, S., Fan, Y., Kumagai, A., Kawakita, E., Kitada, M., Kanasaki, K., and Koya, D. (2020). Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance through the CXCL12\/CXCR4\/mTOR\/TGFbeta Signaling Pathway in Breast Cancer Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030805"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"8679","DOI":"10.18632\/oncotarget.14412","article-title":"DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1067\/mob.2003.169","article-title":"Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade","volume":"188","author":"Khin","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bbapap.2004.09.028","article-title":"Dipeptidyl peptidase IV in tumor progression","volume":"1751","author":"Kikkawa","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_85","first-page":"2278","article-title":"Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells","volume":"63","author":"Kajiyama","year":"2003","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1349-7006.2009.01378.x","article-title":"The expression of dipeptidyl peptidase IV (DPPIV\/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells","volume":"101","author":"Kajiyama","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3892\/ol.2015.3151","article-title":"Expression levels of seprase\/FAPalpha and DPPIV\/CD26 in epithelial ovarian carcinoma","volume":"10","author":"Zhang","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.pan.2016.06.001","article-title":"Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma","volume":"16","author":"Busek","year":"2016","journal-title":"Pancreatology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.2337\/db09-0058","article-title":"Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: Interactions with metformin","volume":"58","author":"Matveyenko","year":"2009","journal-title":"Diabetes"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2337\/db12-1686","article-title":"Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors","volume":"62","author":"Butler","year":"2013","journal-title":"Diabetes"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/dom.12766","article-title":"Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies","volume":"18","author":"Ueberberg","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"E475","DOI":"10.1152\/ajpendo.00025.2013","article-title":"One year of sitagliptin treatment protects against islet amyloid-associated beta-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice","volume":"305","author":"Subramanian","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1210\/en.2017-00027","article-title":"Incretin Therapies Do Not Expand beta-Cell Mass or Alter Pancreatic Histology in Young Male Mice","volume":"158","author":"Cox","year":"2017","journal-title":"Endocrinology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1463-1326.2012.01678.x","article-title":"Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man","volume":"15","author":"Busch","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/s41598-017-19055-6","article-title":"Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis","volume":"8","author":"Pinto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: A meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Cahyadi","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"107981","DOI":"10.1016\/j.diabres.2019.107981","article-title":"Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials","volume":"159","author":"Dicembrini","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00592-020-01479-8","article-title":"Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials","volume":"57","author":"Dicembrini","year":"2020","journal-title":"Acta Diabetol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"9719","DOI":"10.1038\/s41598-018-27965-2","article-title":"The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: A nationwide population-based study in Korea","volume":"8","author":"Lee","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2337\/dc17-0280","article-title":"Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies","volume":"41","author":"Boniol","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.2337\/dc18-2195","article-title":"Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors","volume":"42","author":"Lee","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"k4880","DOI":"10.1136\/bmj.k4880","article-title":"Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: Population based cohort study","volume":"363","author":"Abrahami","year":"2018","journal-title":"BMJ"},{"key":"ref_103","first-page":"952019","article-title":"Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor","volume":"2015","author":"Pech","year":"2015","journal-title":"Case Rep. Endocrinol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2005.05.030","article-title":"KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitr ile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity","volume":"518","author":"Kim","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jdiacomp.2017.01.012","article-title":"Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer","volume":"31","author":"Rathmann","year":"2017","journal-title":"J. Diabetes Complicat."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/ijc.31870","article-title":"Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy","volume":"144","author":"Noh","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clbc.2016.11.002","article-title":"Sitagliptin May Reduce Breast Cancer Risk in Women With Type 2 Diabetes","volume":"17","author":"Tseng","year":"2017","journal-title":"Clin. Breast Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"19057","DOI":"10.18632\/oncotarget.12137","article-title":"Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes","volume":"8","author":"Tseng","year":"2017","journal-title":"Oncotarget"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"711723","DOI":"10.3389\/fpubh.2021.711723","article-title":"Dipeptidyl Peptidase 4 Inhibitors Decrease the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Infection and Type 2 Diabetes Mellitus: A Nationwide Study in Taiwan","volume":"9","author":"Hsu","year":"2021","journal-title":"Front. Public Health"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1038\/s41388-021-01822-5","article-title":"Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma","volume":"40","author":"Kamada","year":"2021","journal-title":"Oncogene"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0168-8278(97)80180-8","article-title":"Aberrant dipeptidyl peptidase IV (DPP IV\/CD26) expression in human hepatocellular carcinoma","volume":"27","author":"Stecca","year":"1997","journal-title":"J. Hepatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.canlet.2018.01.064","article-title":"Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2","volume":"420","author":"Qin","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"115246","DOI":"10.1016\/j.taap.2020.115246","article-title":"Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1\/2, p38alpha, and NF-kappaB signaling","volume":"407","author":"Khalil","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1139\/cjpp-2020-0049","article-title":"Hepatoprotective effect of linagliptin against liver fibrosis induced by carbon tetrachloride in mice","volume":"99","author":"Khattab","year":"2021","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.biopha.2017.02.010","article-title":"Combination of Sitagliptin and Silymarin ameliorates liver fibrosis induced by carbon tetrachloride in rats","volume":"89","author":"Sokar","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/icb.2016.116","article-title":"The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury","volume":"95","author":"Wang","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"103668","DOI":"10.1016\/j.etap.2021.103668","article-title":"Saxagliptin defers thioacetamide-induced hepatocarcinogenesis in rats: A novel suppressive impact on Wnt\/Hedgehog\/Notch1 signaling","volume":"86","author":"Helal","year":"2021","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.molmet.2017.07.016","article-title":"Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease","volume":"6","author":"Baumeier","year":"2017","journal-title":"Mol. Metab."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41598-020-57935-6","article-title":"Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects","volume":"10","author":"Kawakubo","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000491763","article-title":"Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62\/Keap1\/Nrf2-Pentose Phosphate Pathway in a Mouse Model","volume":"8","author":"Kawaguchi","year":"2019","journal-title":"Liver Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Ozutsumi, T., Namisaki, T., Shimozato, N., Kaji, K., Tsuji, Y., Kaya, D., Fujinaga, Y., Furukawa, M., Nakanishi, K., and Sato, S. (2020). Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062164"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/hepr.12860","article-title":"Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis","volume":"47","author":"Okura","year":"2017","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Billeschou, A., Hunt, J.E., Ghimire, A., Holst, J.J., and Kissow, H. (2021). Intestinal Adaptation upon Chemotherapy-Induced Intestinal Injury in Mice Depends on GLP-2 Receptor Activation. Biomedicines, 9.","DOI":"10.3390\/biomedicines9010046"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.regpep.2006.07.003","article-title":"DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells","volume":"137","author":"Masur","year":"2006","journal-title":"Regul. Pept."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/EDE.0000000000000793","article-title":"Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes","volume":"29","author":"Abrahami","year":"2018","journal-title":"Epidemiology"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Ng, L., Foo, D.C., Wong, C.K., Man, A.T., Lo, O.S., and Law, W.L. (2021). Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study. Cancers, 13.","DOI":"10.3390\/cancers13143588"},{"key":"ref_127","first-page":"118","article-title":"A multi-center retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers","volume":"10","author":"Ali","year":"2019","journal-title":"Mol. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/cam4.2278","article-title":"Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study","volume":"8","author":"Bishnoi","year":"2019","journal-title":"Cancer Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1002\/ijc.28260","article-title":"Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats","volume":"133","author":"Femia","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3892\/or.2015.4429","article-title":"The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice","volume":"35","author":"Yorifuji","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.3892\/ol.2017.6698","article-title":"Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation in Apc(Min\/+) mice fed a high-fat diet","volume":"14","author":"Fujiwara","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.biopha.2017.10.149","article-title":"Ameliorative potential of sitagliptin and\/or resveratrol on experimentally-induced clear cell renal cell carcinoma","volume":"97","author":"Kabel","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/onc.2011.298","article-title":"Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation","volume":"31","author":"Arwert","year":"2012","journal-title":"Oncogene"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"8273","DOI":"10.1038\/s41598-017-07921-2","article-title":"Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: A meta-analysis of randomized clinical trials","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/jdi.13192","article-title":"Potential linkage between dipeptidyl peptidase-4 inhibitor use and the risk of pancreatitis\/pancreatic cancer","volume":"11","author":"Shirakawa","year":"2020","journal-title":"J. Diabetes Investig."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e3004","DOI":"10.1002\/dmrr.3004","article-title":"Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis","volume":"34","author":"Overbeek","year":"2018","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.2147\/CMAR.S215107","article-title":"Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus","volume":"11","author":"Choi","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12020-017-1503-2","article-title":"Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells","volume":"59","author":"Kim","year":"2018","journal-title":"Endocrine"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40618-017-0792-x","article-title":"Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells","volume":"41","author":"Kim","year":"2018","journal-title":"J. Endocrinol. Investig."},{"key":"ref_140","first-page":"1010428317722068","article-title":"The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells","volume":"39","author":"Kim","year":"2017","journal-title":"Tumour Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1002\/cam4.3024","article-title":"Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma-associated antigen-A3 expression through Yes-associated protein inactivation","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/iub.2454","article-title":"The mechanism of sitagliptin inhibition of colorectal cancer cell lines\u2019 metastatic functionalities","volume":"73","author":"Carvalho","year":"2021","journal-title":"IUBMB Life"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.tiv.2015.04.019","article-title":"Metformin, but not sitagliptin, enhances WP 631-induced apoptotic HepG2 cell death","volume":"29","author":"Sliwinska","year":"2015","journal-title":"Toxicol. Vitr."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Beckenkamp, A., Willig, J.B., Santana, D.B., Nascimento, J., Paccez, J.D., Zerbini, L.F., Bruno, A.N., Pilger, D.A., Wink, M.R., and Buffon, A. (2015). Differential Expression and Enzymatic Activity of DPPIV\/CD26 Affects Migration Ability of Cervical Carcinoma Cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134305"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/leu.2013.9","article-title":"Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide\u2019s anti-leukemic activity","volume":"27","author":"Spagnuolo","year":"2013","journal-title":"Leukemia"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"18094","DOI":"10.1038\/s41598-019-54695-w","article-title":"DPP8 is a novel therapeutic target for multiple myeloma","volume":"9","author":"Sato","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.exphem.2017.09.012","article-title":"Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph(+) chronic myeloid leukemia","volume":"57","author":"Willmann","year":"2018","journal-title":"Exp. Hematol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinthera.2006.01.015","article-title":"Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers","volume":"28","author":"Bergman","year":"2006","journal-title":"Clin. Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/hepr.12434","article-title":"Synthetic lethal interaction of combined CD26 and Bcl-xL inhibition is a powerful anticancer therapy against hepatocellular carcinoma","volume":"45","author":"Kawaguchi","year":"2015","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jphs.2018.12.004","article-title":"A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4","volume":"139","author":"Yamaguchi","year":"2019","journal-title":"J. Pharmacol. Sci."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Batchu, S.N., Yerra, V.G., Liu, Y., Advani, S.L., Klein, T., and Advani, A. (2020). The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165756"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"119868","DOI":"10.1016\/j.lfs.2021.119868","article-title":"The anti-diabetic drug trelagliptin induces vasodilation via activation of Kv channels and SERCA pumps","volume":"283","author":"Heo","year":"2021","journal-title":"Life Sci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41467-017-01867-9","article-title":"Human CD26(high) T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence","volume":"8","author":"Bailey","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"eaba7443","DOI":"10.1126\/sciadv.aba7443","article-title":"Identification of human CD4(+) T cell populations with distinct antitumor activity","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1172\/JCI40594","article-title":"Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV","volume":"121","author":"Casrouge","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/ni.3201","article-title":"Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy","volume":"16","author":"Laird","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/imcb.12186","article-title":"Differential chemokine receptor expression and usage by pre-cDC1 and pre-cDC2","volume":"96","author":"Cook","year":"2018","journal-title":"Immunol. Cell Biol."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Wilson, A.L., Moffitt, L.R., Wilson, K.L., Bilandzic, M., Wright, M.D., Gorrell, M.D., Oehler, M.K., Plebanski, M., and Stephens, A.N. (2021). DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model. Cancers, 13.","DOI":"10.3390\/cancers13030487"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/carcin\/bgz009","article-title":"The CD26\/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity","volume":"40","author":"Jang","year":"2019","journal-title":"Carcinogenesis"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1089\/scd.2012.0636","article-title":"In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies","volume":"22","author":"Farag","year":"2013","journal-title":"Stem Cells Dev."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"110350","DOI":"10.18632\/oncotarget.22739","article-title":"High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation","volume":"8","author":"Farag","year":"2017","journal-title":"Oncotarget"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2027372","article-title":"Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease","volume":"384","author":"Farag","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/nm.2991","article-title":"Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis","volume":"18","author":"Broxmeyer","year":"2012","journal-title":"Nat. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/ndt\/gfy397","article-title":"Dipeptidyl peptidase-4 inhibitor teneligliptin accelerates recovery from cisplatin-induced acute kidney injury by attenuating inflammation and promoting tubular regeneration","volume":"34","author":"Iwakura","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1080\/01480545.2020.1814319","article-title":"Alogliptin attenuates cyclophosphamide-induced nephrotoxicity: A novel therapeutic approach through modulating MAP3K\/JNK\/SMAD3 signaling cascade","volume":"45","author":"Salama","year":"2020","journal-title":"Drug Chem. Toxicol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1159\/000490688","article-title":"Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy","volume":"43","author":"Jo","year":"2018","journal-title":"Kidney Blood Press. Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4103\/1735-5362.323920","article-title":"Anti-inflammatory effects of saxagliptin and vildagliptin against doxorubicin-induced nephrotoxicity in rats: Attenuation of NLRP3 inflammasome up-regulation and tubulo-interstitial injury","volume":"16","author":"Mostafa","year":"2021","journal-title":"Res. Pharm. Sci."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Iwakura, T., Fukasawa, H., Kitamura, A., Ishibuchi, K., Yasuda, H., and Furuya, R. (2020). Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229377"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1177\/1535370216643418","article-title":"Cardioprotective effects of sitagliptin against doxorubicin-induced cardiotoxicity in rats","volume":"241","author":"Elkablawy","year":"2016","journal-title":"Exp. Biol. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s43440-019-00034-9","article-title":"Bisoprolol and linagliptin ameliorated electrical and mechanical isometric myocardial contractions in doxorubicin-induced cardiomyopathy in rats","volume":"72","author":"Aykan","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1038\/s41598-020-62738-w","article-title":"Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro","volume":"10","author":"Shigematsu","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Abo-Haded, H.M., Elkablawy, M.A., Al-Johani, Z., Al-Ahmadi, O., and El-Agamy, D.S. (2017). Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174295"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"155260","DOI":"10.1016\/j.cyto.2020.155260","article-title":"Stromal cell-derived factor-1alpha predominantly mediates the ameliorative effect of linagliptin against cisplatin-induced testicular injury in adult male rats","volume":"136","author":"Elrashidy","year":"2020","journal-title":"Cytokine"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Lee, J.M., Yoo, I.K., Lee, J.M., Kim, S.H., Choi, H.S., Kim, E.S., Keum, B., Seo, Y.S., Jeen, Y.T., and Chun, H.J. (2019). Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6231-y"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V98.13.3554","article-title":"Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties","volume":"98","author":"Proost","year":"2001","journal-title":"Blood"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.peptides.2006.08.035","article-title":"Stress, NPY and vascular remodeling: Implications for stress-related diseases","volume":"28","author":"Kuo","year":"2007","journal-title":"Peptides"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2957\/kanzo.53.164","article-title":"Spontaneous regression of hepatocellular carcinoma after improving diabetes mellitus: Possibly responsible for immune system","volume":"53","author":"Yamamoto","year":"2012","journal-title":"Kanzo"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.immuni.2006.10.016","article-title":"Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches","volume":"25","author":"Sugiyama","year":"2006","journal-title":"Immunity"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1126\/science.283.5403.845","article-title":"Dependence of human stem cell engraftment and repopulation of NOD\/SCID mice on CXCR4","volume":"283","author":"Peled","year":"1999","journal-title":"Science"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.exphem.2011.10.010","article-title":"Dipeptidyl peptidase IV (DPPIV\/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning","volume":"40","author":"Schwaiger","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/scd.2007.9997","article-title":"Diprotin A infusion into nonobese diabetic\/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34+ peripheral blood cells","volume":"16","author":"Kawai","year":"2007","journal-title":"Stem Cells Dev."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gutjnl-2012-303280","article-title":"Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis","volume":"62","author":"Kissow","year":"2013","journal-title":"Gut"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tem.2016.10.001","article-title":"Glucagon-like Peptide-1 and the Central\/Peripheral Nervous System: Crosstalk in Diabetes","volume":"28","author":"Muscogiuri","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"810469","DOI":"10.1155\/2011\/810469","article-title":"Treatment of streptozotocin-induced diabetic rats with alogliptin: Effect on vascular and neural complications","volume":"2011","author":"Davidson","year":"2011","journal-title":"Exp. Diabetes Res."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","article-title":"NRF2 and the Hallmarks of Cancer","volume":"34","author":"Chapman","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13063-015-0772-4","article-title":"Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: Study protocol for a randomized controlled trial","volume":"16","author":"Baek","year":"2015","journal-title":"Trials"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.stem.2019.02.018","article-title":"Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells","volume":"24","author":"Agarwal","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bjh.16456","article-title":"Dissecting the role of the CXCL12\/CXCR4 axis in acute myeloid leukaemia","volume":"189","author":"Ladikou","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.semcancer.2010.07.001","article-title":"Can inhibition of the SDF-1\/CXCR4 axis eradicate acute leukemia?","volume":"20","author":"Tavor","year":"2010","journal-title":"Semin. Cancer Biol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"E992","DOI":"10.1073\/pnas.1718009115","article-title":"HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice","volume":"115","author":"Devignes","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.pharmthera.2017.05.012","article-title":"Emerging roles of the CXCL12\/CXCR4 axis in pancreatic cancer progression and therapy","volume":"179","author":"Sleightholm","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2013.04.007","article-title":"Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond","volume":"229","author":"Fadini","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.stem.2009.02.013","article-title":"Synergy between CD26\/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction","volume":"4","author":"Zaruba","year":"2009","journal-title":"Cell Stem Cell"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"29393","DOI":"10.1038\/srep29393","article-title":"Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation","volume":"6","author":"Lee","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_198","first-page":"e13495","article-title":"CD26\/Dipeptidyl Peptidase IV and Its Multiple Biological Functions","volume":"13","author":"Pan","year":"2021","journal-title":"Cureus"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ni.2590","article-title":"The transcriptional landscape of alphabeta T cell differentiation","volume":"14","author":"Mingueneau","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.intimp.2013.02.020","article-title":"Impact of different mesenchymal stromal cell types on T-cell activation, proliferation and migration","volume":"15","author":"Najar","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3389\/fimmu.2020.01014","article-title":"MAIT Cell Activation and Functions","volume":"11","author":"Hinks","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10585-019-09966-1","article-title":"The extracellular matrix in tumor progression and metastasis","volume":"36","author":"Eble","year":"2019","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"43854","DOI":"10.1074\/jbc.M405392200","article-title":"Heparan sulfate\/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)\/CXCL12 against proteolysis induced by CD26\/dipeptidyl peptidase IV","volume":"279","author":"Sadir","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2741\/4682","article-title":"Targeting fibroblast activation protein in cancer\u2014Prospects and caveats","volume":"23","author":"Busek","year":"2018","journal-title":"Front. Biosci."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"e002837","DOI":"10.1136\/jitc-2021-002837","article-title":"DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma","volume":"9","author":"Fitzgerald","year":"2021","journal-title":"J. Immunother. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2072\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:57:58Z","timestamp":1760137078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":205,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["cancers14092072"],"URL":"https:\/\/doi.org\/10.3390\/cancers14092072","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]}}}